News | September 12, 2025
A.forall expands US generics portfolio
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Maria Soler Nunez appointed as Chief Quality Officer
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Hemant Surgical Industries receives order
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Subscribe To Our Newsletter & Stay Updated
